NDA 208073 · Bausch and Lomb INC
Xiidra
Lifitegrast · Ophthalmic · Lymphocyte Function-Associated Antigen-1 Antagonist
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Apr 4, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Jul 11, 2016
Approved uses
1
Original approval plus efficacy supplements
Registered trials
34
6 Phase 3, 2 recruiting
FAERS reports
16,505
2,977 serious, 298 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 18, 2025.
Xiidra ® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of the signs and symptoms of dry eye disease (DED). Xiidra (lifitegrast ophthalmic solution) 5% is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the treatment of the signs and symptoms of dry eye disease (DED). ( 1 )
Mechanism: Lifitegrast binds to the integrin LFA-1, a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). ICAM-1 may be overexpressed in corneal and conjunctival tissues in DED. LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell activation and migration to target tissues. In vitro studies demonstrated that lifitegrast may inhibit T-cell adhesion to ICAM-1 in a human T-cell line and may inhibit secretion of inflammatory cytokines in human peripheral blood...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 11, 2016 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewLetterLabel
1 products under this application
- XIIDRA · LIFITEGRAST 5% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Lifitegrast" as an intervention, any sponsor and status, largest first.
- Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye DiseasePivotal-lookingRecruiting
Lunan Better Pharmaceutical Co., LTD.Industry
NCT06879782 · 820 participants (planned) · Start Mar 28, 2024 · Primary completion Mar 28, 2026
Drug: Drug placebo · For: Dry Eye Disease (DED)
Sites: Beijing, China
- A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry EyePivotal-lookingCompleted
ShireTakeda (TAK)
NCT01743729 · 720 participants · Start Dec 7, 2012 · Primary completion Oct 1, 2013
Drug: Lifitegrast; Placebo · For: Dry Eye Disease
Sites: Artesia, California; Hemet, California; Lancaster, California · 31 sites in all
- A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT02284516 · 711 participants · Start Nov 6, 2014 · Primary completion Oct 5, 2015
Drug: Lifitegrast; Placebo · For: Dry Eye Disease
Sites: Birmingham, Alabama; Chandler, Arizona; Artesia, California · 41 sites in all
- Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT01421498 · 588 participants · Start Aug 29, 2011 · Primary completion Apr 28, 2012
Drug: Lifitegrast; Placebo · For: Keratoconjunctivitis Sicca; Dry Eye Disease
Sites: Waterbury, Connecticut; Louisville, Kentucky; Augusta, Maine · 13 sites in all
- A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye DiseasePivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT07128628 · 443 participants · Start Oct 24, 2025 · Primary completion May 28, 2026
Drug: Lifitegrast/Perfluorohexyloctane Fixed Dose Combination; Lifitegrast and 4 more · For: Dry Eye Disease
Sites: Phoenix, Arizona; Glendale, California; Long Beach, California · 32 sites in all
- A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory TreatmentPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07025811 · 378 participants · Start Jul 9, 2025 · Primary completion Jul 16, 2026
Drug: Vevye®; Xiidra® · For: Dry Eye Disease
Sites: Newport Beach, California; Louisville, Kentucky; Andover, Massachusetts · 8 sites in all
- A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye DiseasePivotal-lookingCompleted
Surface Ophthalmics, Inc.Industry
NCT04734197 · 349 participants · Start Jan 11, 2021 · Primary completion Mar 25, 2022
Drug: SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate); Mycophenolic Acid 0.1% and 5 more · For: Dry Eye Disease
Sites: Phoenix, Arizona; Azusa, California; Hemet, California · 40 sites in all
- Safety Study of Lifitegrast to Treat Dry EyePivotal-lookingCompleted
ShireTakeda (TAK)
NCT01636206 · 332 participants · Start Oct 16, 2012 · Primary completion Mar 3, 2014
Drug: Lifitegrast; Placebo · For: Dry Eye Disease
Sites: Artesia, California; Hemet, California; Laguna Hills, California · 23 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- eye irritation2,780
- vision blurred2,679
- drug ineffective1,629
- eye pain1,460
- instillation site pain1,283
- dry eye1,187
- dysgeusia1,118
- instillation site reaction1,019
- ocular hyperaemia707
- lacrimation increased636
- headache629
- visual impairment587
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 4 |
| 2016 | 630 |
| 2017 | 1,846 |
| 2018 | 1,538 |
| 2019 | 1,189 |
| 2020 | 1,976 |
| 2021 | 2,129 |
| 2022 | 2,489 |
| 2023 | 1,922 |
| 2024 | 1,097 |
| 2025 | 985 |
| 2026 | 700 |
Recalls
2 FDA enforcement reports for this application.
May 10, 2022 · Class III · Terminated
Failed Impurities/Degradation Specifications.
May 10, 2022 · Class III · Terminated
Failed Impurities/Degradation Specifications.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xiidra (Lifitegrast)
2024 spending
$505M
Beneficiaries
166,361
477,354 claims
Per beneficiary
$3,038
$11.19 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $28,032,943 |
| 2021 | $261,124,341 |
| 2022 | $332,509,806 |
| 2023 | $472,699,911 |
| 2024 | $505,334,180 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical pharmacologic treatments for dry eye disease: A systematic review.
Tong L, Liu Z, Şahin A, et al. · Ocul Surf 2025 · Systematic Review, Research Support, Non-U.S. Gov't
- A Clinical Evaluation of Lifitegrast Ophthalmic Solution 5% in Symptomatic Contact Lens Wearers.
Schulze MM, Guthrie SE, Ho B, et al. · Clin Ophthalmol 2025 · Case Reports, Clinical Trial
- Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease.
White DE, Hendrix LH, Sun L, et al. · J Manag Care Spec Pharm 2023 · Clinical Trial, Phase II
- Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
Sheppard JD, Torkildsen GL, Lonsdale JD, et al. · Ophthalmology 2014 · Clinical Trial, Phase III, Multicenter Study
- LipiFlow for the treatment of dry eye disease.
Pucker AD, Yim TW, Rueff E, et al. · Cochrane Database Syst Rev 2024 · Systematic Review
- Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease.
Nichols KK, Donnenfeld ED, Karpecki PM, et al. · Eur J Ophthalmol 2019 · Clinical Trial, Phase II, Clinical Trial, Phase III
Sponsor: Bausch and Lomb INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.